BiVACOR Inc.

BiVACOR Inc. has raised $9.0M in total funding. The most recent round was Series B.

BiVACOR Inc. is headquartered in Huntington Beach, CA.

Replacing Hearts. Restoring Lives. HEART FAILURE Heart failure is a global epidemic affecting at least 26 million people worldwide, 6.2 million adults in the U.S., and is increasing in prevalence. Heart transplantations are reserved for those with severe heart failure and

Severe heart failure affects millions worldwide, but only about 6,000 donor hearts are available for transplant each year and drug therapy offers limited help for these patients.

BiVACOR has developed a Total Artificial Heart (TAH), an implantable electro-mechanical rotary blood pump that replaces both native ventricles, currently in an FDA-approved first-in-human Early Feasibility Study as a bridge-to-transplant device.

Unlike current TAH technology that uses flexible polymer diaphragms, the page states BiVACOR's device uses a single motor with one magnetically levitated (MAGLEV) rotor and no valves, flexing chambers, or mechanical bearings, built in titanium and capable of flows over 12 L/min.

Founded by biomedical engineer Daniel Timms to build the Total Artificial Heart; the device has since been implanted in patients at Texas Heart Institute and Duke, and Houston furniture retailer Jim "Mattress Mack" McIngvale was an early investor.